Model for End-stage Liver Disease

Journal of Clinical and Experimental Hepatology

Volumn 3, Issue 1, 2013, Pages 50-60

  Singal, Ashwani K ^a   Kamath, Patrick S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cirrhosis; Liver transplantation; MELD

Indexed keywords

BILIRUBIN; CREATININE;

ALCOHOL LIVER DISEASE; BILIRUBIN BLOOD LEVEL; BLEEDING; CHILD TURCOTTE PUGH SCORE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FULMINANT HEPATIC FAILURE; HEPATITIS; HEPATORENAL SYNDROME; HOSPICE CARE; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; OUTCOME ASSESSMENT; PATIENT REFERRAL; POST TREATMENT SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROGNOSIS; RETRANSPLANTATION; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VARICEAL BLEEDING;

EID: 84875813330     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2012.11.002     Document Type: Review

References (137)

1. Lucey M.R., Brown K.A., Everson G.T., et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997, 3:628-637.
2. Van Meter C.H. The organ allocation controversy: how did we arrive here?. Ochsner J 1999, 1:6-11.
3. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33:464-470.
4. Malinchoc M., Kamath P.S., Gordon F.D., Peine C.J., Rank J., ter Borg P.C. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000, 31:864-871.
5. Brandsaeter B., Friman S., Broome U., et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003, 38:1176-1183.
6. Said A., Williams J., Holden J., et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004, 40:897-903.
7. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124:91-96.
8. Wiesner R.H., McDiarmid S.V., Kamath P.S., et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001, 7:567-580.
9. Cholongitas E., Papatheodoridis G.V., Vangeli M., Terreni N., Patch D., Burroughs A.K. Systematic review: the model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?. Aliment Pharmacol Ther 2005, 22:1079-1089.
10. Cholongitas E., Senzolo M., Patch D., et al. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 2006, 23:883-893.
11. Charlton M.R., Wall W.J., Ojo A.O., et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009, 15:S1-S34.
12. Sharma P., Welch K., Eikstadt R., Marrero J.A., Fontana R.J., Lok A.S. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl 2009, 15:1142-1148.
13. Nair S., Verma S., Thuluvath P.J. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002, 35:1179-1185.
14. Gish R.G. Do we need to MEND the MELD?. Liver Transpl 2007, 13:486-487.
15. Asrani S.K., Kim W.R. Model for end-stage liver disease: end of the first decade. Clin Liver Dis 2011, 15:685-698.
16. Huo T.I., Hsu C.Y., Lin H.C., et al. Selecting an optimal cutoff value for creatinine in the model for end-stage liver disease equation. Clin Transplant 2010, 24:157-163.
17. Cholongitas E., Marelli L., Kerry A., et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007, 13:523-529.
18. Cirillo M., Anastasio P., De Santo N.G. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 2005, 20:1791-1798.
19. Leithead J.A., MacKenzie S.M., Ferguson J.W., Hayes P.C. Is estimated glomerular filtration rate superior to serum creatinine in predicting mortality on the waiting list for liver transplantation?. Transplant Int 2011, 24:482-488.
20. Huo S.C., Huo T.I., Lin H.C., et al. Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation?. Transplantation 2007, 84:1406-1412.
21. Francoz C., Prie D., Abdelrazek W., et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl 2010, 16:1169-1177.
22. Schouten J.N., Francque S., Van Vlierberghe H., et al. The influence of laboratory-induced MELD score differences on liver allocation: more reality than myth. Clin Transplant 2012, 26:E62-E70.
23. Trotter J.F., Olson J., Lefkowitz J., Smith A.D., Arjal R., Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007, 7:1624-1628.
24. Tripodi A., Chantarangkul V., Primignani M., et al. The international normalized ratio calibrated for cirrhosis (INR (liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007, 46:520-527.
25. Heuman D.M., Mihas A.A., Habib A., et al. MELD-XI: a rational approach to " sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl 2007, 13:30-37.
26. Botta F., Giannini E., Romagnoli P., et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003, 52:134-139.
27. Wiesner R., Lake J.R., Freeman R.B., Gish R.G. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl 2006, 12:S85-S87.
28. Brown R.S., Lake J.R. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant 2005, 5:203-204.
29. Oberkofler C.E., Dutkowski P., Stocker R., et al. Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Crit Care 2010, 14:R117.
30. Dutkowski P., Oberkofler C.E., Bechir M., et al. The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis. Liver Transpl 2011, 17:674-684.
31. Bambha K., Kim W.R., Benson J., et al. Economic impact of meld-based allocation of liver transplants. Am J Transplant 2005, 5:425.
32. Aberg F., Maklin S., Rasanen P., et al. Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score. Liver Transpl 2011, 17:1333-1343.
33. Moylan C.A., Brady C.W., Johnson J.L., Smith A.D., Tuttle-Newhall J.E., Muir A.J. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008, 300:2371-2378.
34. Mathur A.K., Schaubel D.E., Gong Q., Guidinger M.K., Merion R.M. Racial and ethnic disparities in access to liver transplantation. Liver Transpl 2010, 16:1033-1040.
35. Myers R.P., Shaheen A.A., Aspinall A.I., Quinn R.R., Burak K.W. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J Hepatol 2011, 54:462-470.
36. Zhang M., Yin F., Chen B., et al. Pretransplant prediction of posttransplant survival for liver recipients with benign end-stage liver diseases: a nonlinear model. PloS ONE 2012, 7:e31256.
37. Rana A., Hardy M.A., Halazun K.J., et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008, 8:2537-2546.
38. Dutkowski P., Oberkofler C.E., Slankamenac K., et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg 2011, 254:745-753. discussion 53.
39. Briceno J., Ciria R., de la Mata M., Rufian S., Lopez-Cillero P. Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease score era. Transplantation 2010, 90:530-539.
40. Gyori G.P., Silberhumer G.R., Zehetmayer S., et al. Dynamic changes in MELD score not only predict survival on the waiting list but also overall survival after liver transplantation. Transplant Int 2012, 25:935-940.
41. Silberhumer G.R., Pokorny H., Hetz H., et al. Combination of extended donor criteria and changes in the model for end-stage liver disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation 2007, 83:588-592.
42. Ling Q., Xu X., Wei Q., et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. PloS ONE 2012, 7:e30322.
43. Halldorson J.B., Bakthavatsalam R., Fix O., Reyes J.D., Perkins J.D. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transplant 2009, 9:318-326.
44. Weismuller T.J., Fikatas P., Schmidt J., et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany - limitations of the 'sickest first'-concept. Transplant Int 2011, 24:91-99.
45. Angermayr B., Luca A., Konig F., et al. Aetiology of cirrhosis of the liver has an impact on survival predicted by the model of end-stage liver disease score. Eur J Clin Invest 2009, 39:65-71.
46. Ahmad J., Bryce C.L., Cacciarelli T., Roberts M.S. Differences in access to liver transplantation: disease severity, waiting time, and transplantation center volume. Ann Intern Med 2007, 146:707-713.
47. Argo C.K., Stukenborg G.J., Schmitt T.M., Kumer S.C., Berg C.L., Northup P.G. Regional variability in symptom-based MELD exceptions: a response to organ shortage?. Am J Transplant 2011, 11:2353-2361.
48. Ravaioli M., Masetti M., Ridolfi L., et al. Laboratory test variability and model for end-stage liver disease score calculation: effect on liver allocation and proposal for adjustment. Transplantation 2007, 83:919-924.
49. Ioannou G.N., Perkins J.D., Carithers R.L. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008, 134:1342-1351.
50. Wiesner R.H., Freeman R.B., Mulligan D.C. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004, 127:S261-S267.
51. Washburn K., Edwards E., Harper A., Freeman R. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010, 10:1643-1648.
52. Massie A.B., Caffo B., Gentry S.E., et al. MELD exceptions and rates of waiting list outcomes. Am J Transplant 2011, 11:2362-2371.
53. Park C.W., Tsai N.T., Wong L.L. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 2011, 25:E606-E611.
54. Cucchetti A., Cescon M., Bertuzzo V., et al. Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation?. Am J Transplant 2011, 11:1696-1704.
55. Toso C., Dupuis-Lozeron E., Majno P., et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012, 56:149-156.
56. Nadim M.K., Sung R.S., Davis C.L., et al. Simultaneous liver-kidney transplantation Summit: current state and future directions. Am J Transplant 2012.
57. Singal A., Wiesner R.H. Contemporary predictors of simultaneous liver kidney transplantation and impact on liver graft and patient outcomes. Gastroenterology 2012, 142:S433.
58. Sharma P., Schaubel D.E., Guidinger M.K., Goodrich N.P., Ojo A.O., Merion R.M. Impact of MELD-based allocation on end-stage renal disease after liver transplantation. Am J Transplant 2011, 11:2372-2378.
59. Eason J.D., Gonwa T.A., Davis C.L., Sung R.S., Gerber D., Bloom R.D. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008, 8:2243-2251.
60. Merion R.M., Schaubel D.E., Dykstra D.M., Freeman R.B., Port F.K., Wolfe R.A. The survival benefit of liver transplantation. Am J Transplant 2005, 5:307-313.
61. Wiencke K., Boberg K.M. Current consensus on the management of primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol 2011, 35:786-791.
62. Volk M.L., Lok A.S., Pelletier S.J., Ubel P.A., Hayward R.A. Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology 2008, 135:1568-1574.
63. Axelrod D.A., Lentine K.L., Salvalaggio P.R., Schnitzler M.A. The cost and quality paradox. Am J Transplant 2009, 9:985-986.
64. Antaki F., Lukowski A. The model for end-stage liver disease (MELD) predicts survival of liver cirrhosis patients after discharge to hospice. J Clin Gastroenterol 2007, 41:412-415.
65. Medici V., Rossaro L., Wegelin J.A., et al. The utility of the model for end-stage liver disease score: a reliable guide for liver transplant candidacy and, for select patients, simultaneous hospice referral. Liver Transpl 2008, 14:1100-1106.
66. Kremers W.K., van I.M., Kim W.R., et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004, 39:764-769.
67. Katoonizadeh A., Decaestecker J., Wilmer A., et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int 2007, 27:329-334.
68. Taylor R.M., Davern T., Munoz S., et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology 2006, 44:1589-1597.
69. Schmidt L.E., Larsen F.S. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007, 45:789-796.
70. Sharma P., Schaubel D.E., Gong Q., Guidinger M., Merion R.M. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. Hepatology 2012, 55:192-198.
71. Sheth M., Riggs M., Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002, 2:2.
72. Srikureja W., Kyulo N.L., Runyon B.A., Hu K.Q. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 2005, 42:700-706.
73. Zapata-Irrison L., Jurado-Nunez J., Altamirano-Gomez J. [do MELD or Maddrey?: comparison of 2 forecasting models in patients with hepatitis toxic alcohol.]. Revista de gastroenterologia de Mexico 2008, 73:57-62.
74. Dunn W., Jamil L.H., Brown L.S., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005, 41:353-358.
75. Verma S., Ajudia K., Mendler M., Redeker A. Prevalence of septic events, type 1 hepatorenal syndrome, and mortality in severe alcoholic hepatitis and utility of discriminant function and MELD score in predicting these adverse events. Dig Dis Sci 2006, 51:1637-1643.
76. Jeong J.Y., Sohn J.H., Son B.K., et al. [Comparison of model for end-stage liver disease score with discriminant function and Child-Turcotte-Pugh scores for predicting short-term mortality in Korean patients with alcoholic hepatitis]. Korean J Gastroenterol = Taehan Sohwagi Hakhoe Chi 2007, 49:93-99.
77. O'Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology 2010, 51:307-328.
78. Alessandria C., Ozdogan O., Guevara M., et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005, 41:1282-1289.
79. Kraja B., Sina M., Mone I., et al. Predictive value of the model of end-stage liver disease in cirrhotic patients with and without spontaneous bacterial peritonitis. Gastroenterol Res Pract 2012, 2012:539059.
80. Obstein K.L., Campbell M.S., Reddy K.R., Yang Y.X. Association between model for end-stage liver disease and spontaneous bacterial peritonitis. Am J Gastroenterol 2007, 102:2732-2736.
81. Viasus D., Garcia-Vidal C., Castellote J., et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine 2011, 90:110-118.
82. Chen C.H., Shih C.M., Chou J.W., et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver Int 2011, 31:417-424.
83. Chalasani N., Kahi C., Francois F., et al. Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology 2002, 35:1282-1284.
84. Schepke M., Appenrodt B., Heller J., Zielinski J., Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006, 26:834-839.
85. Singal A., Kamath P.S. Variceal Hemorrhage 2012, Elsevier, New Delhi, India.
86. Feyssa E., Ortiz J., Grewal K., et al. MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation. Transplantation 2011, 91:786-792.
87. Garrison R.N., Cryer H.M., Howard D.A., Polk H.C. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984, 199:648-655.
88. O'Leary J.G., Yachimski P.S., Friedman L.S. Surgery in the patient with liver disease. Clin Liver Dis 2009, 13:211-231.
89. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988, 319:983-989.
90. Mansour A., Watson W., Shayani V., Pickleman J. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 1997, 122:730-735. discussion 5-6.
91. Causey M.W., Steele S.R., Farris Z., Lyle D.S., Beitler A.L. An assessment of different scoring systems in cirrhotic patients undergoing nontransplant surgery. Am J Surg 2012, 203:589-593.
92. Teh S.H., Nagorney D.M., Stevens S.R., et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology 2007, 132:1261-1269.
93. Kim S.H., Han Y.D., Lee J.G., et al. MELD-based indices as predictors of mortality in chronic liver disease patients who undergo emergency surgery with general anesthesia. J Gastrointest Surg 2011, 15:2029-2035.
94. Costa B.P., Sousa F.C., Serodio M., Carvalho C. Value of MELD and MELD-based indices in surgical risk evaluation of cirrhotic patients: retrospective analysis of 190 cases. World J Surg 2009, 33:1711-1719.
95. Kim S.Y., Yim H.J., Park S.M., et al. Validation of a Mayo post-operative mortality risk prediction model in Korean cirrhotic patients. Liver Int 2011, 31:222-228.
96. Cho H.C., Jung H.Y., Sinn D.H., et al. Mortality after surgery in patients with liver cirrhosis: comparison of Child-Turcotte-Pugh, MELD and MELD Na score. Eur J Gastroenterol Hepatol 2011, 23:51-59.
97. Neeff H., Mariaskin D., Spangenberg H.C., Hopt U.T., Makowiec F. Perioperative mortality after non-hepatic general surgery in patients with liver cirrhosis: an analysis of 138 operations in the 2000s using Child and MELD scores. J Gastrointest Surg 2011, 15:1-11.
98. Hoteit M.A., Ghazale A.H., Bain A.J., et al. Model for end-stage liver disease score versus Child score in predicting the outcome of surgical procedures in patients with cirrhosis. World J Gastroenterol 2008, 14:1774-1780.
99. Delis S., Bakoyiannis A., Madariaga J., Bramis J., Tassopoulos N., Dervenis C. Laparoscopic cholecystectomy in cirrhotic patients: the value of MELD score and Child-Pugh classification in predicting outcome. Surg Endosc 2010, 24:407-412.
100. Kao H.K., Guo L.F., Cheng M.H., et al. Predicting postoperative morbidity and mortality by model for endstage liver disease score for patients with head and neck cancer and liver cirrhosis. Head Neck 2011, 33:529-534.
101. Filsoufi F., Salzberg S.P., Rahmanian P.B., et al. Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl 2007, 13:990-995.
102. Marrocco-Trischitta M.M., Kahlberg A., Astore D., Tshiombo G., Mascia D., Chiesa R. Outcome in cirrhotic patients after elective surgical repair of infrarenal aortic aneurysm. J Vasc Surg 2011, 53:906-911.
103. Ailawadi G., Lapar D.J., Swenson B.R., et al. Model for end-stage liver disease predicts mortality for tricuspid valve surgery. Ann Thorac Surg 2009, 87:1460-1467. discussion 7-8.
104. Bonde P., Ku N.C., Genovese E.A., et al. Model for end-stage liver disease score predicts adverse events related to ventricular assist device therapy. Ann Thorac Surg 2012, 93:1541-1547. discussion 7-8.
105. Matthews J.C., Pagani F.D., Haft J.W., Koelling T.M., Naftel D.C., Aaronson K.D. Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation 2010, 121:214-220.
106. Maithel S.K., Kneuertz P.J., Kooby D.A., et al. Importance of low preoperative platelet count in selecting patients for resection of hepatocellular carcinoma: a multi-institutional analysis. J Am Coll Surg 2011, 212:638-648. discussion 48-50.
107. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
108. Teh S.H., Sheppard B.C., Schwartz J., Orloff S.L. Model for end-stage liver disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis. Am J Surg 2008, 195:697-701.
109. Rahbari N.N., Garden O.J., Padbury R., et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011, 149:713-724.
110. Hsu K.Y., Chau G.Y., Lui W.Y., Tsay S.H., King K.L., Wu C.W. Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of model for end-stage liver disease score. World J Surg 2009, 33:2412-2419.
111. Delis S.G., Bakoyiannis A., Biliatis I., Athanassiou K., Tassopoulos N., Dervenis C. Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma. HPB 2009, 11:351-357.
112. Cescon M., Cucchetti A., Grazi G.L., et al. Indication of the extent of hepatectomy for hepatocellular carcinoma on cirrhosis by a simple algorithm based on preoperative variables. Arch Surg 2009, 144:57-63. discussion.
113. Garcia-Tsao G., Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010, 362:823-832.
114. Singal A.K., Jampana S., Singal V., Kuo Y.F. Presence of hepatocellular carcinoma is a predictor of in-patient mortality from acute variceal hemorrhage amongst patients with cirrhosis: analysis of National Inpatient Sample (1998-2007). Hepatology 2011, 54:1368A-1369A.
115. Cerqueira R.M., Andrade L., Correia M.R., Fernandes C.D., Manso M.C. Risk factors for in-hospital mortality in cirrhotic patients with oesophageal variceal bleeding. Eur J Gastroenterol Hepatol 2012, 24:551-557.
116. Amitrano L., Guardascione M.A., Bennato R., Manguso F., Balzano A. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. J Hepatol 2005, 42:820-825.
117. Bambha K., Kim W.R., Pedersen R., Bida J.P., Kremers W.K., Kamath P.S. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut 2008, 57:814-820.
118. Chen W.T., Lin C.Y., Sheen I.S., et al. MELD score can predict early mortality in patients with rebleeding after band ligation for variceal bleeding. World J Gastroenterol 2011, 17:2120-2125.
119. Flores-Rendon A.R., Gonzalez-Gonzalez J.A., Garcia-Compean D., Maldonado-Garza H.J., Garza-Galindo A.A. Model for end stage of liver disease (MELD) is better than the Child-Pugh score for predicting in-hospital mortality related to esophageal variceal bleeding. Ann Hepatol 2008, 7:230-234.
120. Orloff M.J., Vaida F., Isenberg J.I., et al. Child-Turcotte score versus MELD for prognosis in a randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis. J Surg Res 2012.
121. Inaba K., Barmparas G., Resnick S., et al. The model for end-stage liver disease score: an independent prognostic factor of mortality in injured cirrhotic patients. Arch Surg 2011, 146:1074-1078.
122. Kim H.J., Larson J.J., Lim Y.S., et al. Impact of MELD on waitlist outcome of retransplant candidates. Am J Transplant 2010, 10:2652-2657.
123. Bambha K., Kim W.R., Kremers W.K., et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 2004, 4:1798-1804.
124. Kim W.R., Biggins S.W., Kremers W.K., et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008, 359:1018-1026.
125. Moini M., Hoseini-Asl M.K., Taghavi S.A., et al. Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation. Clin Transplant 2011, 25:638-645.
126. Serste T., Gustot T., Rautou P.E., et al. Severe hyponatremia is a better predictor of mortality than MELD Na in patients with cirrhosis and refractory ascites. J Hepatol 2012, 57:274-280.
127. Londono M.C., Cardenas A., Guevara M., et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007, 56:1283-1290.
128. Leise M.D., Kim W.R., Kremers W.K., Larson J.J., Benson J.T., Therneau T.M. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011, 140:1952-1960.
129. Vaa B.E., Asrani S.K., Dunn W., Kamath P.S., Shah V.H. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc 2011, 86:37-42.
130. Sharma P., Schaubel D.E., Sima C.S., Merion R.M., Lok A.S. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008, 135:1575-1581.
131. Barber K., Madden S., Allen J., Collett D., Neuberger J., Gimson A. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation 2011, 92:469-476.
132. Magder L.S., Regev A., Mindikoglu A.L. Comparison of seven liver allocation models with respect to lives saved among patients on the liver transplant waiting list. Transplant Int 2012, 25:409-415.
133. Suk K.T., Kim C.H., Park S.H., et al. Comparison of hepatic venous pressure gradient and two models of end-stage liver disease for predicting the survival in patients with decompensated liver cirrhosis. J Clin Gastroenterol 2012.
134. Ferlitsch M., Reiberger T., Hoke M., et al. Von Willebrand factor as new non-invasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012.
135. Cervoni J.P., Thevenot T., Weil D., et al. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012, 56:1299-1304.
136. Liu F., Cai L.Y., Zhong L., et al. Model for end-stage liver disease combined with serum prealbumin to predict the prognosis of patients with decompensated liver cirrhosis. J Dig Dis 2010, 11:352-357.
137. Bechmann L.P., Jochum C., Kocabayoglu P., et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol 2010, 53:639-647.